search Created with Sketch.
search Created with Sketch.

Advertisement

Topic: Eczema

DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS thumbnail
Play Button

DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS

Series: DermWire TV | October 29, 2020

The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic Surgery and Aesthetic Dermatology conference features more than 72 hours of content over four days. Pfizer’s abrocitinib receives priority review designation from FDA for AD.

Watch Video
DermWireTV: Zilxi Launch, Eczema Awareness, Uninsurance Rates thumbnail
Play Button

DermWireTV: Zilxi Launch, Eczema Awareness, Uninsurance Rates

Series: DermWire TV | October 8, 2020

For eczema awareness month,  the National Eczema Association (NEA) is offering  virtual educational programs, community engagement activities, and additional free resources. Georgia, Oklahoma, and Texas have the highest rates of uninsurance. Zilxi minocycline topical foam launches as  new data from the National Rosacea Society reveals an age gap in rosacea treatment approaches. 

Watch Video
DermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration thumbnail
Play Button

DermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration

Series: DermWire TV | August 27, 2020

Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasis of the face;” the report supported by Galderma provides findings of a global survey involving over 600 patients with facial rosacea or psoriasis and 361 doctors across six countries. Dr. Shereene Idriss discusses Galderma’s “Face Up to Rosacea” campaign featuring celebrity stylist and E! TV personality Brad Goreski. The 300mg single-dose pre-filled pen for Dupixent is now available. MC2 Therapeutics is partnering with EPI Health on the commercialization of Wynzora Cream in the US.

Watch Video
DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin thumbnail
Play Button

DermWireTV: Clinical Support Tech Data; Dupixent, Stelara Updates; Rihanna Launches Fenty Skin

Series: DermWire TV | August 13, 2020

A feasibility study in collaboration between LEO Innovation Lab, VisualDX, and the German Association of Dermatological Prevention supports technology to assist in diagnosis of skin conditions. Leo Pharma’s investigational JAK inhibitor delgocitinib cream is  Fast Tracked by the FDA for the potential treatment of adults with moderate-to-severe chronic hand eczema. Two new studies reinforce the efficacy and safety of Dupixent for the treatment of atopic dermatitis in children and adults. Stelara is now approved for pediatric patients, 6-11 years of age, with moderate to severe plaque psoriasis. Look for Rihanna’s new Fenty Skin line under the umbrella of skincare offerings. 

Watch Video
DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates thumbnail
Play Button

DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates

Series: DermWire TV | July 30, 2020

The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Dermatology's Climate Change Committee. FDA has approved MC2 Therapeutics Wynzora Cream for once-daily topical treatment of plaque psoriasis in adults. Tremfya is the first IL-23 inhibitor FDA-approved for active psoriatic arthritis. AbbVie's upadacitinib met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis.

Watch Video

Advertisement

The Latest in Eczema

Advertisement

View more